Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1250-1256, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schlosser, U.
Right arrow Articles by Schmitz, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schlosser, U.
Right arrow Articles by Schmitz, G.

Clinical Chemistry, Vol 42, 1250-1256, Copyright © 1996 by American Association for Clinical Chemistry

Calpastatin autoantibodies: detection, epitope mapping, and development of a specific peptide ELISA

U Schlosser, KJ Lackner, C Scheckenhofer and G Schmitz
Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany.

Autoantibodies against calpastatin (CAST) were detected in a 53-year- old female patient with a history of arthritis and thrombosis. The specificity of the autoantibodies was determined by screening expression cDNA libraries, sequence analysis of positive clones, and subsequent Western blotting against recombinant antigen. Because the Western blot lacked satisfactory reproducibility, an ELISA for anti- CAST antibodies was established. The major epitope recognized by 24 Western blot-positive sera was located within the C-terminal 27 amino acids. The ELISA was therefore based on a synthetic peptide representing these amino acids. The assay was calibrated with serial dilutions of a positive reference serum. Intraassay precision is high with a CV of approximately 4% for low- and high-titer samples. Interassay precision (CV) was 5.6-8.2% for sera with low and intermediate titers [10-60 arbitrary units (AU), where 1:100 dilution of the positive reference serum = 100 AU, 1:1000 dilution = 10 AU, etc.], which increases with higher titers ( > 60 AU). Among 205 healthy blood donors, the mean + 3 SD (after logarithmic transformation) was 30 AU; higher values were seen in 2.9% of 138 hospitalized patients. The newly developed ELISA will be a useful tool for further clinical studies on the association of anti-CAST antibodies to disease, because it permits rapid and reproducible analysis of patient sera.


The following articles in journals at HighWire Press have cited this article:


Home page
 LupusHome page
V Salle, O Vittecoq, F Jouen-Beades, J F Menard, J P Ducroix, M Godin, X Le Loet, and F Tron
Autoantibodies recognizing the 27 carboxy-terminal amino acids of calpastatin are associated with secondary Sjogren syndrome in systemic lupus erythematosus
Lupus, October 1, 2004; 13(10): 800 - 804.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
O. Vittecoq, V. Salle, F. Jouen-Beades, K. Krzanowska, J. F. Menard, A. Gayet, P. Fardellone, P. Tauveron, X. Le Loet, and F. Tron
Autoantibodies to the 27 C-terminal amino acids of calpastatin are detected in a restricted set of connective tissue diseases and may be useful for diagnosis of rheumatoid arthritis in community cases of very early arthritis
Rheumatology, October 1, 2001; 40(10): 1126 - 1134.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.